Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Up 2.7%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)’s stock price shot up 2.7% during mid-day trading on Thursday . The company traded as high as $7.57 and last traded at $7.35. 3,235,019 shares were traded during trading, a decline of 51% from the average session volume of 6,666,061 shares. The stock had previously closed at $7.16.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC reiterated a “buy” rating and set a $17.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th.

Recursion Pharmaceuticals Price Performance

The stock’s 50 day moving average is $8.82 and its two-hundred day moving average is $9.90. The stock has a market capitalization of $1.75 billion, a PE ratio of -4.59 and a beta of 0.83.

Recursion Pharmaceuticals (NASDAQ:RXRX) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The firm had revenue of $13.80 million during the quarter, compared to the consensus estimate of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.34) earnings per share. On average, equities analysts predict that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher Gibson sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total transaction of $386,500.00. Following the completion of the sale, the chief executive officer now owns 863,524 shares in the company, valued at $6,675,040.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Recursion Pharmaceuticals news, COO Tina Marriott sold 3,000 shares of the stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $8.78, for a total value of $26,340.00. Following the completion of the transaction, the chief operating officer now owns 535,457 shares in the company, valued at $4,701,312.46. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $7.73, for a total value of $386,500.00. Following the completion of the transaction, the chief executive officer now owns 863,524 shares of the company’s stock, valued at approximately $6,675,040.52. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 207,359 shares of company stock valued at $1,704,435. 15.75% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Deutsche Bank AG increased its position in shares of Recursion Pharmaceuticals by 15.4% in the third quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock valued at $457,000 after buying an additional 7,973 shares in the last quarter. Federated Hermes Inc. acquired a new stake in Recursion Pharmaceuticals in the 3rd quarter worth about $153,000. AXQ Capital LP acquired a new position in shares of Recursion Pharmaceuticals in the 3rd quarter valued at about $222,000. Alps Advisors Inc. lifted its stake in shares of Recursion Pharmaceuticals by 10.5% in the 3rd quarter. Alps Advisors Inc. now owns 156,214 shares of the company’s stock valued at $1,195,000 after purchasing an additional 14,818 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in shares of Recursion Pharmaceuticals by 165.3% in the 3rd quarter. Citigroup Inc. now owns 470,512 shares of the company’s stock valued at $3,599,000 after purchasing an additional 293,174 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.